| Name | Yourgene Health |
|---|---|
| Epic | YGEN |
| Isin | GB00BN31ZD89 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.52p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £16.45 | Debt ratio | n/a |
| Shares in issue | 3,176.96 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -7.6 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.3 | 52-week high / low | 0.20p / 5.65p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Yourgene Health |
|---|---|
| Address | Skelton House, Lloyd Street North, Manchester Science Park, Manchester, United Kingdom, M15 6SH |
| Telephone | +44 (0)161 669 8122 |
| Website | http://www.yourgene-health.com/ |
| Director | Position |
|---|---|
| Mr Lyn Rees | CEO |
| Ms Mary G Tavener | Non-Executive Director |
| Mr Jonathan Seaton | Non-Executive Director |
| Mr Andrew (Andy) Leeser | Non-Executive Director |
| Dr Bill Chang | Executive Director |
| Dr John Brown | Non-Executive Chairman |
| Mr Joanne Mason | Chief Science Officer |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/03/22 | 31/03/21 | 31/03/20 |
| Intangible asssets and goodwill | 21.81 | 23.93 | 21 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 42.32 | 33.39 | 27.68 |
| Inventory / work in progress | 5.99 | 2.9 | 1.15 |
| Trade and other receivables | 6.98 | 5.33 | 5.63 |
| Cash and equivalents | 8.43 | 7 | 2.76 |
| Other current assets and asset held for resale | 0.34 | 0.51 | 0.45 |
| Total of all assets | 64.06 | 49.13 | 37.68 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 12.25 | 8.77 | 6.47 |
| Long term liabilities | 19.07 | 7.43 | 4.9 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 31.32 | 16.2 | 11.38 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 32.74 | 32.92 | 26.3 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 32.67 | 32.67 | 32.56 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -46.59 | -44.88 | -33.49 |
| Share premium account | 67.79 | 67.26 | 51.18 |
| Total equity | 32.74 | 32.92 | 26.3 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.54 | -11.71 | -3.24 |
| Pre-tax profit | -3.19 | -12 | -3.38 |